Literature DB >> 3801279

Enhancing effect of bromovinyldeoxyuridine on antitumour activity of 5-fluorouracil in mice bearing MOPC-315 plasmacytomas.

S Ben-Efraim, S Shoval, E de Clercq.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3801279      PMCID： PMC2001541          DOI： 10.1038/bjc.1986.250

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  8 in total

1.  Adaptation of murine MOPC-315 myeloma cells to growth in vitro and further characterization of their C-type viruses.

Authors:  A Yaniv; A Gazit; M Dvir; D Guthmann; E Eylan
Journal:  Eur J Cancer       Date:  1978-07       Impact factor: 9.162

2.  Mouse myeloma proteins with antihapten antibody acitivity. The protein produced by plasma cell tumor MOPC-315.

Authors:  H N Eisen; E S Simms; M Potter
Journal:  Biochemistry       Date:  1968-11       Impact factor: 3.162

3.  Effect of (E)-5-(2-bromovinyl)uracil on the catabolism and antitumor activity of 5-fluorouracil in rats and leukemic mice.

Authors:  C Desgranges; G Razaka; E De Clercq; P Herdewijn; J Balzarini; F Drouillet; H Bricaud
Journal:  Cancer Res       Date:  1986-03       Impact factor: 12.701

4.  Melphalan-mediated potentiation of antitumor immune responsiveness of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.

Authors:  R C Bocian; S Ben-Efraim; S Dray; M B Mokyr
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

5.  Regeneration of the antiviral drug (E)-5-(2-bromovinyl)-2'-deoxyuridine in vivo.

Authors:  C Desgranges; G Razaka; F Drouillet; H Bricaud; P Herdewijn; E De Clercq
Journal:  Nucleic Acids Res       Date:  1984-02-24       Impact factor: 16.971

Review 6.  Synthesis and antiviral properties of 5-vinylpyrimidine nucleoside analogs.

Authors:  E De Clercq; R T Walker
Journal:  Pharmacol Ther       Date:  1984       Impact factor: 12.310

7.  The difference between 5-fluorouracil and melphalan in their ability to promote antitumor immune response against MOPC-315 plasmacytoma.

Authors:  S Ben-Efraim; S Shoval; R Ophir
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Cellular basis for the inefficacy of 5-FU in human colon carcinoma.

Authors:  B Drewinko; L Y Yang
Journal:  Cancer Treat Rep       Date:  1985-12
  8 in total
  1 in total

1.  5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil.

Authors:  D P Baccanari; S T Davis; V C Knick; T Spector
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-01       Impact factor: 11.205
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.